Daily Pharma News - 17 October 2026

Welcome to PharmacoLearn's daily roundup of the most important pharmaceutical and healthcare news for pharmacy students in India. Today's top stories span drug patent policy reform, state-level regulatory enforcement, Indian pharma M&A, quarterly earnings, oncology drug development, and a global alliance against counterfeit medicines.

India Overhauls Drug Patent Guidelines to Curb Evergreening - Faster Entry for Cheap Generics

India's patent office has issued draft guidelines that take direct aim at drug evergreening - the practice of extending patent monopolies through minor modifications such as new salt forms, crystal forms, or other small tweaks to an existing medicine. Under the new norms, applicants will have to produce hard clinical data proving superior therapeutic efficacy before such follow-on patents can be granted. For pharmacy students, this is a textbook application of Section 3(d) of the Indian Patents Act, the same provision that famously upheld access to affordable medicines in the Novartis-Glivec litigation. The move signals that India's regulatory posture continues to favour the domestic generics industry - often called the "pharmacy of the world" - by closing loopholes that delay cheaper generic alternatives from reaching patients.

If implemented, the guidelines could accelerate generic entry across therapy areas and reduce litigation around secondary patents. Students of pharmaceutical jurisprudence and drug regulatory affairs should watch how these drafts evolve, because they will shape patent prosecution strategy for innovators and filing opportunities for generic manufacturers alike.

Punjab's Anti-Drug Crackdown: Rs. 20.6 Crore Medicines Seized, 520 Chemist Licences Suspended

Punjab's drug enforcement wing has seized medicines worth Rs. 20.6 crore and suspended 520 retail chemist licences following a sweeping inspection drive against illegal stocking and sale of habit-forming drugs. Reports indicate nearly 17,000 inspections were conducted between April 2025 and September 2026, making this one of the state's largest pharmaceutical enforcement actions in recent years. The crackdown targets pharmacies dispensing narcotic and psychotropic formulations without valid prescriptions - a direct violation of the Drugs and Cosmetics Act and the NDPS Act.

For B.Pharm and D.Pharm students, this story is a stark reminder of the legal responsibilities that come with a drug licence: record-keeping for Schedule H, H1 and X drugs, prescription verification, and ethical dispensing are not academic exercises but statutory duties with real consequences. Regulatory enforcement of this scale also highlights career opportunities in drug inspectorates and state pharmacy councils for pharmacists who take compliance seriously.

Mankind Pharma Acquires 70% Stake in Belgium's ACTx for EUR 48 Million - Entry into European CDMO Market

Mankind Pharma has announced the acquisition of a 70% stake in ACTx (Armed Cell Therapeutics), a Belgium-based contract development and manufacturing organisation (CDMO), for EUR 48 million (around Rs. 511 crore). The deal marks Mankind's entry into the European CDMO services market and significantly expands its global manufacturing footprint. For an Indian company long associated with affordable domestic brands, this is a notable strategic pivot toward high-value contract manufacturing for regulated international markets.

The acquisition reflects a broader trend of Indian pharmaceutical companies moving up the value chain - from volume generics toward biologics, cell therapy and contract services. Pharmacy students interested in industrial pharmacy, quality assurance and regulatory affairs should note that CDMO partnerships demand compliance with EU-GMP standards, opening skilled career pathways in manufacturing, validation and quality control.

Solara Active Pharma Q2 Results: Rs. 28 Crore Net Profit, Revenue Up 33% on Strong API Demand

Chennai-based Solara Active Pharma has reported a net profit of Rs. 28 crore for Q2 FY27, with revenue up 33% to Rs. 417.8 crore, driven by strong demand for active pharmaceutical ingredients (APIs). The turnaround sent the company's shares rallying about 16% following the announcement. Solara, a pure-play API manufacturer, benefits from the global push to diversify supply chains for bulk drugs - a theme that has favoured Indian API producers in recent years.

The result is worth studying for pharmacy students following pharmaceutical management and industry trends: API manufacturing sits upstream of every finished formulation, so its margins and volumes act as an early indicator of demand across the pharma value chain. Solara's recovery also illustrates how operational efficiency and product mix can restore profitability in a commodity-linked segment.

Chipscreen Biosciences Gets NMPA IND Approval for PD-L1 Antibody Conjugate NW001

China's National Medical Products Administration (NMPA) has granted investigational new drug (IND) approval to Chipscreen Biosciences for NW001, a PD-L1-targeted epigenetic immune-modulating antibody conjugate. The molecule links an anti-PD-L1 antibody to an HDAC (histone deacetylase) inhibitor, combining immune checkpoint blockade with epigenetic modulation in a single conjugate - a first-in-class design aimed at improving response in cancers where checkpoint inhibitors alone fall short.

For pharmacology and medicinal chemistry students, NW001 is an elegant case study in rational drug design: it pairs a targeted biologic with a small-molecule epigenetic agent to attack tumours through two complementary mechanisms. The IND clearance opens the door to Phase 1 trials, and the programme underscores how China's biotech sector continues to push novel oncology modalities alongside Western innovators.

CHMP Recommends TALVEY (Talquetamab) Plus Daratumumab for Earlier-Line Multiple Myeloma

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended approval of Johnson & Johnson's TALVEY (talquetamab) in combination with daratumumab for earlier-line treatment of relapsed or refractory multiple myeloma. TALVEY is a GPRC5D-directed bispecific T-cell engager, while daratumumab is the established anti-CD38 monoclonal antibody - and moving the combination into earlier lines of therapy could reshape myeloma treatment sequencing in Europe.

This development matters for pharmacology and clinical pharmacy students because bispecific antibodies represent one of the fastest-growing classes in oncology. A positive CHMP opinion typically precedes European Commission authorisation, and the decision also has relevance for India, where myeloma therapy is increasingly discussed in terms of biosimilar daratumumab access and the eventual arrival of bispecifics in emerging markets.

WHO and INTERPOL Form Landmark Alliance Against Counterfeit Medicines

The World Health Organization and INTERPOL have announced a landmark alliance to combat medical crime and counterfeit medicines, signed on 16 October 2026. The pact aims to dismantle transnational networks trafficking substandard and falsified medicines and to strengthen global health security through coordinated enforcement and intelligence-sharing. Counterfeit medicines remain a major public health threat - particularly in low- and middle-income countries - causing treatment failures, antimicrobial resistance and loss of trust in health systems.

For Indian pharmacy students, this story connects directly to the day's domestic enforcement news: while Punjab acts at the retail level, WHO and INTERPOL are tackling the same problem at its source. The alliance is expected to boost surveillance, cross-border investigations and public awareness - and it reinforces why pharmacists, as the last checkpoint before a medicine reaches a patient, are central to the fight against falsified products.

Conclusion

17 October 2026 brought a regulatory-heavy news day with a clear theme: systems tightening up in favour of patients. India's anti-evergreening patent norms promise cheaper generics, Punjab's crackdown defends dispensing ethics, the WHO-INTERPOL pact confronts counterfeit networks globally, and Europe's CHMP moved a cutting-edge myeloma combination closer to patients. Meanwhile, Indian industry pressed forward - Mankind Pharma's Belgian acquisition and Solara's earnings rebound show domestic companies competing confidently on the world stage, while China's NMPA greenlit an innovative oncology molecule. For pharmacy students, the takeaway is practical: stay current on patent law, regulatory enforcement, industry strategy and drug development - these are the forces that will shape your profession, and they are all moving today.

References

← All daily news